On March 6, 2023 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Nick Edmunds, Chief Technology Officer at Mission, will be presenting at the Targeted Protein Degradation Europe conference 2023 (Press release, Mission Therapeutics, MAR 6, 2023, View Source [SID1234628236]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mission Therapeutics’ presentation will take place 9am Thursday, March 30th, 2023, at The Tower Hotel, St Katharine’s Way, London, E1W 1LD. The presentation will cover the Development of a DUB Inhibitor Platform & Emerging Data from a USP30 Inhibitor, based on Mission’s recent research. It has been highlighted as one of 5 key talks not to miss by the conference organisers.

The event, which will take place in London, 28th-30th March, is the Leading Forum Showcasing Key Stakeholders & Expert Minds from the European Degradation Community. The conference is returning to London for its third year to discuss key topics in what is expected to be a landmark year for the degradation community.

Prospective attendees can register for the event here: View Source

If you would like to meet with Nick and the team at TPD Europe, please contact [email protected].